Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

InnoCare Planning $250 Million IPO on Hong Kong Exchange

publication date: May 9, 2019

Beijing InnoCare Pharma is planning a Hong Kong IPO that could raise as much as $250 million and value the company at a minimum of $800 million, according to informed sources. InnoCare is still early in the process and has not yet chosen investment bankers for the offering. The company, which is developing immunotherapies for cancer and autoimmune diseases, has three molecules in or near clinical trials, including its lead product, a BTK inhibitor that is currently being tested in multiple Phase II trials for cancer. More details....

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022